Navigation Links
Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
Date:10/22/2007

initive evidence as to whether IVUS can identify patients at heightened risk for stent thrombosis."

The IVUS sub-study is expected to confirm the collaborative work of Dr. Antonio Colombo and his associates who identified IVUS parameters as independent predictors of stent thrombosis. In his findings, Dr. Colombo has demonstrated a high rate of IVUS-detected stent under-expansion and incomplete stent apposition (ISA) when bare-metal stents (BMS) have been implanted via angiographic guidance alone. Additionally, similar findings regarding stent under-expansion and residual edge stenoses have been discussed in numerous retrospective reports published since 2002 regarding acute and sub-acute BMS and DES thrombosis. Volcano's Eagle Eye(R) Gold IVUS catheters will be used in all sub-study patients at the initiation of the sub-study and in follow-up assessments. Analysis will include assessment of lesion morphology by using both traditional grayscale IVUS and Volcano's proprietary VH(TM) IVUS tissue characterization technology.

"The S.T.L.L.R. study* by Costa, et al, has shown that geographic miss is a contributing factor to poor stenting outcomes and stent thrombosis. We expect that the ADAPT-DES IVUS sub-study will confirm what many interventionalists already intuitively know-- that accurate stent placement really can reduce stent thrombosis and that IVUS is an effective, efficient way to optimize stent results," said Scott Huennekens, President & CEO, Volcano Corporation. "Volcano's sponsorship of this large sub-study represents a major commitment of resources for our company. Our leadership in sponsoring this clinical study again reinforces Volcano's commitment to advancing the field of interventional cardiology and improving patient safety and care."

About Volcano Corporation

Volcano Corporation offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart diseases and gui
'/>"/>

SOURCE Volcano Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008).... 1 Vical Incorporated (...$1.0 million milestone payment from Merck & Co...hase I clinical trial of an investigational plasmi... is based on Vical,s DNA gene delivery technology ... (hTERT). hTERT is the subject of separate license...
(Date:11/28/2008)...Nov. 28 Eli Lilly and Co...al New Drug Application (sNDA) from,the U.S. Food...loxetine HCl),for the management of chronic pain....irst half of 2009, adding data from a recently com...ain of the knee. , The decision does not af...
(Date:11/26/2008)... to 406 Subjects , , FRANKLIN, Mass., Nov. ... Bulletin Board: PLCSF) announced today that it ha...ug Administration (FDA) for its U.S. pivotal trial...Guard System(TM) and associated therapy in the pr... , The FDA also approved PLC,s request to ex...
(Date:11/25/2008)...CISCO, Calif., Nov. 25 Proteolix, ...f novel therapeutics that target,protein degradat...day,announced that data from two ongoing Phase 2 ...a will be presented at the upcoming 50th Annual Me.... Carfilzomib is the first in a new class,of spe...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Longs Drugs Partners With Google on the Launch of Google Health 19817 1Longs Drugs Partners With Google on the Launch of Google Health 19817 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 1bioMETRX Expands Engineering and Manufacturing Capabilities 3366 2bioMETRX Expands Engineering and Manufacturing Capabilities 3366 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 1TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 2TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 3TAK 390MR Phase 3 data presented at Digestive Disease Week 19814 4Greener offices make happier employees 19812 1Greener offices make happier employees 19812 2
...itional Findings Reported on Glucose Homeostasis E...ne 25, 2007 /PRNewswire-FirstCall/ -- In a 14-day,... doses of the,investigational compound dapaglifloz...ansporter 2 (SGLT2) administered alone or,concomit...tes, no,discontinuations due to adverse events and...
...VILLE, Colo., June 26, 2007 /PRNewswire-FirstCall/...hree Phase I trials,studying REP8839, a novel topi...vity against major skin pathogens including,methic...he Phase I,trials show that topically applied REP8...th low systemic exposure, or drug,absorption into ...
Other Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 2Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 3Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839 4
(Date:12/1/2008)...S, Dec. 2 While many Ame...ic challenges including rising costs of,basic nec...ess Scripts,(Nasdaq: ESRX ) has expanded Rx Out...escription medicines. , (Logo: http://www...OGO ) , Lower-income consumers can now rece...
(Date:12/1/2008)...O New research reveals that computed tomography (...y, has the potential to screen for two diseases at...hich commonly affect adults over age 50. Results o...meeting of the Radiological Society of North Ameri...to screening for colorectal cancer, we were able t...
(Date:12/1/2008)... Warren Presents Award, Engages with President on ...ome and Abroad During Saddleback Civil Forum on Gl...ire/ -- President George W. Bush was honored on th...he "International Medal of PEACE" given by Dr. Ric...uring the Saddleback Civil Forum on Global Health....
(Date:12/1/2008)...ls shut down and stop dividing when their DNA is d... so as to prevent damaged DNA from leading to unre...r, a new study, published in this week,s issue of ...ut down they also spew proteins into their surroun...s up conditions that support the development of ag...
Breaking Medicine News(10 mins):Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 2Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 3Health News:Amid Economic Crisis, Express Scripts Offers Easy and Affordable Way for Lower-Income Consumers to Get Six-Month Supply of Prescription Medicines 4Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 2Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 3Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 4Health News:President George W. Bush Receives 'International Medal of PEACE' That Coincides With PEPFAR Milestone on World Aids Day: 5Health News:Escape cancer, but age sooner? The dark side of the tumor suppressing process 2
...em to be linked to extremely low frequency electro... of print in Occupational and Environmental Medic...wiss railway workers, who were monitored for 30 ye...opted to study this group, because railway workers...
...cials have confirmed the first human case of avian... The Ministry of Health has officially confirmed t...eadly H5N1 virus, two days after the suspected cas...ing to Vietnam News Agency. The man, from Vinh Ph...
...tudy by neurologists at the University of Arkansas...und a link between the increasingly popular weigh... serious neurological conditions. Katalin Juhasz...in the UAMS Department of Neurology, is lead autho...
...own that too much heat can decrease sperm count, a...the Bourn Hall Clinic in Cambridgeshire have sugge...ot be the best preparation for fathering a child. ...hat a foreign break develops their probability of ...
Other Medicine News:Health News:Link Between Gastric Bypass Surgery and Neurological Conditions 2
Fome-Cuf® tubes can breathe with the patient to provide a safe, effective, and low pressure seal throughout the ventilatory cycle.
The TTS™ tracheostomy tubes are available in both neonatal and pediatric sizes., ,The TTS™ tube is like an uncuffed tube, but it has a cuff. When completely deflated, it collapses tight
Indications For Usage: ,Bypass upper airway obstructions, provide long term ventilation, support and/or manage tracheal/bronchial secretions.
...l spiral reinforced. X-ray opaque . Low volume cuf...ange: The flange can be adjusted along the tube sh...sue. The lock ring is turned clockwise until the f...atient Comfort: The tube is soft and flexible for ...
Medicine Products: